Company: OPGN
Filing Date: 2025-10-31
Form Type: 10-Q
Source: 0001829126-25-008771
Chunk: 1

Company: OPGEN INC
Filing Date: 2025-10-31
Form: 10-Q
Item: Part I, Item 1
Chunk 1
---
 and December 31, 2024

    2

    2

    Common stock, $0.01 par value; 100,000,000 shares authorized; 10,071,286 and 10,070,779 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively

    100,713

    100,708

    Additional paid-in capital

    300,963,393

    300,780,440

    Accumulated deficit

    (290,398,663
    )

    (293,500,522
    )
  
    Total stockholders’ equity

    10,665,445

    7,380,628

    Total liabilities and stockholders’ equity
     
    $
    13,243,521

    $
    9,862,698

See accompanying notes to unaudited condensed consolidated financial statements.

1

OpGen, Inc. and Subsidiaries

Condensed
Consolidated Statements of Operations and Comprehensive Income (Loss)

(unaudited)

    Three Months Ended June 30,

    Six Months Ended
    June 30,

    2025

    2024

    2025

    2024

    Revenue

    Product sales
     
    $
    -

    $
    28,000

    $
    -

    $
    169,373

    Laboratory services

    -

    -

    -

    26,776

    Listing sponsorship services

    4,000,000

    -

    4,000,000

    -

    Total revenue

    4,000,000

    28,000

    4,000,000

    196,149

    Operating expenses

    Cost of products sold

    -

    (41,600
    )

    -

    31,636

    Cost of services

    -

    -

    -

    1,575

    Research and development, net

    -

    22,964

    -

    48,820

    General and administrative

    594,838

    1,568,619

    1,108,182

    3,252,770

    Sales and marketing

    2,387

    25,327

    11,889

    153,973

    Total operating expenses